The maker of cannabis-derived medications, including Sativex and Epidiolex, recorded a net loss for the quarter of $50.1 million compared with a year-ago net loss of $69.5 million.
GW Pharma trades on the Nasdaq under the ticker symbol GWPH.
Epidiolex, Sativex maker GW Pharmaceuticals reports Q1 revenue, loss improvement
Latest Headlines
- Tribes in two states considering cannabis opportunities
- Missouri licenses 192 medical marijuana dispensaries
- Alaska licenses state-approved social cannabis consumption
- California to require marijuana retailers to exhibit QR code
- 9,000 vape cartridges recalled from Detroit medical cannabis store
- BC’s adult-use cannabis sales spike in November to pace Canadian growth
- Aphria secures CA$100 million injection from anonymous investor
- No edibles under New Zealand’s medical cannabis scheme, government says
- Report: Thailand issues 442 medical cannabis licenses, but full market access years away
- German pharmacies have new pharmaceutical CBD supplier
Business can expect new markets, fresh opportunities - and more pitfalls.